Condition
Peritoneal Malignant Mesothelioma
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed2
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05001880Phase 2RecruitingPrimary
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT02399371Phase 2Completed
Pembrolizumab in Treating Patients With Malignant Mesothelioma
NCT05449366Phase 1CompletedPrimary
Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma
NCT05193006UnknownPrimary
Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma
Showing all 4 trials